tirzepatide being discontinued FDA Announces End To Compounded By March 19, 2025 Adults with obesity who discontinue

Why it matters: Compounded drugs can typically only be sold when the branded forms theyre mimicking are in shortage

Tirzepatide is a dual GLP-1/GIP receptor agonist that acts on two hormone pathways involved in appetite and metabolism

10.1038/nrc2980 63 KalraS

Medicare GLP-1 Bridge Program Open Now Wegovy, Zepbound, and oral Wegovy covered at approximately $50/month for eligible Medicare beneficiaries

Microglia mediate host defense against infectious pathogens, harmful self-proteins such as A, aggregated -synuclein, mutant or oxidized superoxide dismutase, mutant huntingtin or prions, as well as primary or metastatic CNS tumors (Hickman et al., 2018)

This test identifies genetic predispositions in your GLP1R, GIPR, FTO, and MC4R genes, helping determine whether semaglutide matches your individual physiology